Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study
Biological and Pharmaceutical Bulletin · 2023
DOI: 10.1248/bpb.b22-00794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Tomoki Hori und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nara Prefecture General Medical Center. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nara Prefecture General Medical Center.
- Department of Pharmacy, Kobe University Hospital.
- Department of Respiratory Medicine, Nara Prefecture General Medical Center.
Zitieren
APA
Hori, T., Yamamoto, K., Ito, T., Ikushima, S., Omura, T., & Yano, I. (2023). Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b22-00794
Vancouver
Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b22-00794
BibTeX
@article{Hori2023,
author = {Hori, Tomoki and Yamamoto, Kazuhiro and Ito, Takefumi and Ikushima, Shigeki and Omura, Tomohiro and Yano, Ikuko},
title = {Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study},
journal = {Biological and Pharmaceutical Bulletin},
year = {2023},
doi = {10.1248/bpb.b22-00794}
}
EUVIMED